- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISBN
-
9783540640301
3540640304
- Maße
-
25 cm
- Umfang
-
XI, 285 S.
- Sprache
-
Englisch
- Anmerkungen
-
Literaturverz. S. 277 - 285
- Erschienen in
-
Recent results in cancer research ; 148
- Schlagwort
-
Krebs
Therapie
Kosten-Nutzen-Analyse
- Ereignis
-
Veröffentlichung
- (wo)
-
Berlin, Heidelberg, New York, Barcelona, Budapest, Hong Kong, London, Milan, Paris, Santa Clara, Singapore, Tokyo
- (wer)
-
Springer
- (wann)
-
1998
- Urheber
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 14:10 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Neymark, Niels
- Springer
Entstanden
- 1998
Ähnliche Objekte (12)
Ocular side effects of novel anti-cancer biological therapies
Clinical development of targeted and immune based anti-cancer therapies
Association between the antioxidant properties of SESN proteins and anti-cancer therapies
Common anti-cancer therapies induce somatic mutations in stem cells of healthy tissue
Development of novel parvovirus-based anticancer therapies
Optimization of personalized therapies for anticancer treatment
A Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy
Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
Progress in anti-cancer chemotherapy
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Targeting CDK9 for anti-cancer therapeutics
Erratum to: miRNAs: micro-managers of anticancer combination therapies
Ocular side effects of novel anti-cancer biological therapies
Clinical development of targeted and immune based anti-cancer therapies
Association between the antioxidant properties of SESN proteins and anti-cancer therapies
Common anti-cancer therapies induce somatic mutations in stem cells of healthy tissue
Development of novel parvovirus-based anticancer therapies
Optimization of personalized therapies for anticancer treatment
A Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy
Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
Progress in anti-cancer chemotherapy
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Targeting CDK9 for anti-cancer therapeutics
Erratum to: miRNAs: micro-managers of anticancer combination therapies
Ocular side effects of novel anti-cancer biological therapies
Clinical development of targeted and immune based anti-cancer therapies
Association between the antioxidant properties of SESN proteins and anti-cancer therapies
Common anti-cancer therapies induce somatic mutations in stem cells of healthy tissue
Development of novel parvovirus-based anticancer therapies
Optimization of personalized therapies for anticancer treatment
A Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy
Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
Progress in anti-cancer chemotherapy
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Targeting CDK9 for anti-cancer therapeutics